Lonza will commence its partnership with Teva to develop, manufacture and market biosimilar medicines in the first quarter of 2009. Stefan Borgas, Lonza’s Chief Executive Officer said Lonza's capabilities in the area of biologics manufacturing will add value to this joint venture to produce the copycat products
Reuters
Tuesday 20 January 2009
Lonza in biosimilars deal with Teva
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment